Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice

Vaccine

Volumn 31, Issue 47, 2013, Pages 5594-5601

  Ondondo, Beatrice ^a   Brennan, Caroline ^b   Nicosia, Alfredo ^c,d   Crome, Steven J ^b   Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Huntington Life Sciences Ltd   (United Kingdom)

^c Okairòs ^*  (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Chimpanzee adenovirus; Conserved regions of HIV 1; HIV 1 vaccines; Modified vaccinia virus Ankara (MVA); Plasmid DNA; Pre clinical toxicity

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE; TOXICITY TESTING;

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALP; ALT; ASPARTATE AMINOTRANSFERASE; AST; CHIMPANZEE ADENOVIRUS; CONSERVED REGIONS OF HIV-1; ERYTHROCYTE; GAMMA-GLUTAMYL TRANSPEPTIDASE; GGT; HAEMATOCRIT; HAEMOGLOBIN; HB; HCT; HIV-1 VACCINES; LARGE UNSTAINED CELLS; LUC; MCHC; MCV; MEAN CELL HAEMOGLOBIN CONCENTRATION; MEAN CELL VOLUME; MODIFIED VACCINIA VIRUS ANKARA; MODIFIED VACCINIA VIRUS ANKARA (MVA); MVA; PLASMID DNA; PLATELET; PLT; PRE-CLINICAL TOXICITY; RBC; TOTAL WHITE CELL COUNT; WBC;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; DRUG CARRIERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV-1; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED BALB C; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84886798981     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.068     Document Type: Article

References (15)

1. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366(April (14)):1275-1286.
2. Hanke T., McMichael A.J. HIV-1: from iscapism to conservatism. Eur J Immunol 2011, 41:3390-3393.
3. Letourneau S., Im E.J., Mashishi T., Brereton C., Bridgeman A., Yang H., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007, 2(10):e984.
4. Im E-J., Hong J.P., Roshorm Y., Bridgeman A., Létourneau S., Liljeström P., et al. Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog 2011, 7:e1002041.
5. Knudsen M.L., Mbewe-Mvula A., Rosario M., Johansson D.X., Kakoulidou M., Bridgeman A., et al. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to conventional plasmid DNA vaccine. J Virol 2012, 86(February):4082-4090.
6. Letourneau S., Im E-J., Mashishi T., Brereton C., Bridgeman A., Yang H., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007, 2:e984.
7. Rosario M., Borthwick N., Stewart-Jones G.B., Mbewe-Mwula A., Bridgeman A., Colloca S., et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 2012, 26:275-284.
8. Rosario M., Bridgeman A., Quakkelaar E.D., Quigley M.F., Hill B.J., Knudsen M.L., et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 2010, 40(May):1973-1984.
9. Hanke T., McMichael A.J., Samuel R.S., Powell L.A.J., McLoughlin L., Crome S.J., et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 2002, 21:109-115.
10. Hanke T., McMichael A.J., Dennise M.J., Sharpe S.A., Powell L.A.J., Loughlin l Mc., et al. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 2005, 23:1507-1514.
11. Barnes E., Folgori A., Capone S., Swadling L., Aston S., Kurioka A., et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012, 4(January (115)):ra1.
12. Hanke T., Goonetilleke N., McMichael A.J., Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J Gen Virol 2007, 88:1-12.
13. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205(March (5)):772-781.
14. Sheehy S.H., Duncan C.J., Elias S.C., Biswas S., Collins K.A., O'Hara G.A., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 2012, 7(2):e31208.
15. Sheehy S.H., Duncan C.J., Elias S.C., Collins K.A., Ewer K.J., Spencer A.J., et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2012, 19(December (12)):2269-2276.